Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Merle

Showing results (101-110 of 113) with videos related to

Pageof 12
Sort By:
Clinical and Translational Gastroenterology|July 12, 2019
A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular CarcinomaR K Kelley, E Gane, E Assenat, et al.
ESMO Gastrointestinal Oncology|April 17, 2026
Regorafenib use in patients with unresectable hepatocellular carcinoma: analyses of subgroups of special interest in the observational REFINE studyY J Kim, P Merle, R S Finn, et al.
Alimentary Pharmacology & Therapeutics|August 16, 2006
Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective studyC Bonny, H Fontaine, T Poynard, et al.
BMC Geriatrics|October 12, 2019
Prevalence of Potentially Inappropriate Medication use in older driversGuohua Li, Howard F Andrews, Stanford Chihuri, et al.
ESMO Open|May 28, 2025
Health-related quality of life analysis of the LEAP-002 study of lenvatinib plus pembrolizumab versus lenvatinib as first-line treatment for advanced hepatocellular carcinomaR S Finn, M Kudo, P Merle, et al.
Journal of Hepatology|March 22, 2026
Molecularly guided therapies for advanced primary liver cancers refractory to systemic treatment: Results from the 2025 French Genomic Medicine InitiativeC Campani, P Laurent Puig, F Villeret, et al.
Physical Review Letters|January 22, 2002
Neutral pion threshold production at Q(2) = 0.05 GeV(2)/c(2) and chiral perturbation theoryH Merkel, P Bartsch, D Baumann, et al.
Physical Review Letters|April 17, 2002
Measurement of the beam-helicity asymmetry in the p((-->)e,e'p)pi(0) reaction at the energy of the Delta(1232) resonanceP Bartsch, D Baumann, J Bermuth, et al.
Oncoimmunology|August 16, 2019
Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)M Moehler, J Heo, H C Lee, et al.
Techniques in Coloproctology|January 10, 2024
Screening for precancerous anal lesions linked to human papillomaviruses: French recommendations for clinical practiceL Spindler, I Etienney, L Abramowitz, et al.
Pageof 12

Showing results (101-110 of 113) with videos related to

Sort By:
Pageof 12
Clinical and Translational Gastroenterology|July 12, 2019
A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular CarcinomaR K Kelley, E Gane, E Assenat, et al.
ESMO Gastrointestinal Oncology|April 17, 2026
Regorafenib use in patients with unresectable hepatocellular carcinoma: analyses of subgroups of special interest in the observational REFINE studyY J Kim, P Merle, R S Finn, et al.
Alimentary Pharmacology & Therapeutics|August 16, 2006
Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective studyC Bonny, H Fontaine, T Poynard, et al.
BMC Geriatrics|October 12, 2019
Prevalence of Potentially Inappropriate Medication use in older driversGuohua Li, Howard F Andrews, Stanford Chihuri, et al.
ESMO Open|May 28, 2025
Health-related quality of life analysis of the LEAP-002 study of lenvatinib plus pembrolizumab versus lenvatinib as first-line treatment for advanced hepatocellular carcinomaR S Finn, M Kudo, P Merle, et al.
Journal of Hepatology|March 22, 2026
Molecularly guided therapies for advanced primary liver cancers refractory to systemic treatment: Results from the 2025 French Genomic Medicine InitiativeC Campani, P Laurent Puig, F Villeret, et al.
Physical Review Letters|January 22, 2002
Neutral pion threshold production at Q(2) = 0.05 GeV(2)/c(2) and chiral perturbation theoryH Merkel, P Bartsch, D Baumann, et al.
Physical Review Letters|April 17, 2002
Measurement of the beam-helicity asymmetry in the p((-->)e,e'p)pi(0) reaction at the energy of the Delta(1232) resonanceP Bartsch, D Baumann, J Bermuth, et al.
Oncoimmunology|August 16, 2019
Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)M Moehler, J Heo, H C Lee, et al.
Techniques in Coloproctology|January 10, 2024
Screening for precancerous anal lesions linked to human papillomaviruses: French recommendations for clinical practiceL Spindler, I Etienney, L Abramowitz, et al.
Pageof 12